Qiang Liu

机构：Shanghai CASB Biotechnology (China) · ORCID：0009-0003-9286-7399

发表论文 7 篇 · 总被引 31 次 · h-index 3

代表论文

• Economic evaluation of camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma in the United States and China (2024 · International Journal of Clinical Pharmacy · 被引 16)
• Discovery and validation of colorectal cancer tissue-specific methylation markers: a dual-center retrospective cohort study (2024 · Clinical Epigenetics · 被引 7)
• Identification of PSMD2 as a promising biomarker for pancreatic cancer patients based on comprehensive bioinformatics and in vitro studies (2024 · Heliyon · 被引 5)
• Association of Chlamydia trachomatis Infection With Breast Cancer Risk and the Modification Effect of IL-12 (2024 · Clinical Breast Cancer · 被引 2)
• The role of serum acsl4 in differentiating early-stage breast cancer (2025 · European journal of medical research · 被引 1)
• The Novel HLA‐DRB1*09:01:13 Allele, Identified by Sanger Dideoxy Nucleotide Sequencing in a Chinese Individual (2026 · HLA)